Abionyx announced on Friday that it had 1.9 million euros in cash and cash equivalents as of June 30, prior to the receipt of research tax credits.

By way of comparison, the biotech company had cash and cash equivalents of nearly 2.9 million euros as of March 31 and four million euros as of December 31, 2022.

After elimination of intra-group transactions, the company recorded consolidated half-year sales of 2.1 million euros.

Copyright (c) 2023 CercleFinance.com. All rights reserved.